Latest Updates in Breast Cancer
SABCS 2025: Redefining Endocrine-Based Care in HR+, HER2-Negative Breast Cancer Across Early and Metastatic Settings
Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....
SABCS 2025: Transforming HER2+ Breast Cancer Care: Key Updates from HER2CLIMB-05, DESTINY, and PHILA Trials
This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05,...
TUKYSA Combination Improves Progression-Free Survival in First-Line HER2+ Metastatic Breast Cancer: HER2CLIMB-05 Phase 3 Results
TUKYSA combo improves PFS in first-line HER2+ metastatic breast cancer maintenance, the first update to treatment paradigm since 2012.
Datroway Achieves First OS Benefit in Immunotherapy-Ineligible Triple-Negative Breast Cancer
First cancer drug to show OS benefit vs chemotherapy for TNBC patients ineligible for immunotherapy in landmark phase 3 trial.
Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results
Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early breast cancer at seven-year follow-up.
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.
Latest in HER2
SABCS 2025: Transforming HER2+ Breast Cancer Care: Key Updates from HER2CLIMB-05, DESTINY, and PHILA Trials
This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05,...
TUKYSA Combination Improves Progression-Free Survival in First-Line HER2+ Metastatic Breast Cancer: HER2CLIMB-05 Phase 3 Results
TUKYSA combo improves PFS in first-line HER2+ metastatic breast cancer maintenance, the first update to treatment paradigm since 2012.
Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results
Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early breast cancer at seven-year follow-up.
FDA Grants Priority Review to Enhertu Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.
Palbociclib Resistance Biomarkers in Advanced Breast Cancer
ctDNA genotyping reveals ESR1, PIK3CA mutations and CCND1, FGFR1 amplifications predict worse outcomes with palbociclib in HR+/HER2- ABC.
Latest in HR
SABCS 2025: Redefining Endocrine-Based Care in HR+, HER2-Negative Breast Cancer Across Early and Metastatic Settings
Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....
Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results
Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early breast cancer at seven-year follow-up.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.
Palbociclib Resistance Biomarkers in Advanced Breast Cancer
ctDNA genotyping reveals ESR1, PIK3CA mutations and CCND1, FGFR1 amplifications predict worse outcomes with palbociclib in HR+/HER2- ABC.
Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial
Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast cancer: 24-month rates 94.7% vs 90.2% placebo (HR 0.56, p
Latest in Triple Negative Breast Cancer (TNBC)
Datroway Achieves First OS Benefit in Immunotherapy-Ineligible Triple-Negative Breast Cancer
First cancer drug to show OS benefit vs chemotherapy for TNBC patients ineligible for immunotherapy in landmark phase 3 trial.
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.
ENPP1 Inhibition Plus Radiation Prevents Breast Cancer Local Recurrence in Preclinical Models
ENPP1hi circulating tumor cells contribute to relapse by self-seeding mechanism requiring PMN-MDSC infiltration and NET formation.